| SYSTEM |
HIV-1
PR
(NY5 isolate) with inhibitor
L-735,524 [CRIXIVAN (Indinavir)]
|
| HIVdb File |
hiv4msd
|
| PDB File |
1hsg
|
| Company or Laboratory |
Merck Research Laboratories
West Point, PA
|
| Year |
1994
|
| INHIBITOR (Type) |
L-735,524 (hydroxyethylene
isostere)
|
| Composition of the Inhibitor
(Substrate) or Summary Formula |
N - [2(R) - Hydroxy
- 1(S) - Indanyl]- 5 - [(2(S)- Tertiary - butyl amino carbonyl - 4(3 -
pyridyl methyl) piperazino] - 4(S) - Hydroxy - 2(R) - Phenyl methyl penta
amide monohydrate
|
| Schematic Formula |
L-735,524
|
| Resolution |
2Ao
|
| R factor |
0.166
|
| Space Group |
P21212
|
| Dimension of Elementary
Cell |
a=59.57,b=87.07,c=46.71
|
| a,b,g
(alpha,beta,gamma)
|
a=b=g=90
|
| Reference |
Z.Chen, Y.Li, E. Chen, D.L.Hall,
P.L.Darke, C.Culberson, J.A.Shaffer, L.C.Kuo; J.Biol.Chem.,
269, 26344, 1994 |
| Comment |
There is a structure of
HIV-1 PR with inhibitor Indinavir (CRIXIVAN) recently approved by the U.S.
Food and Drug Administration (FDA).There are two structures of HIV-1 PR
and HIV-2 PR with inhibitor L-735,524. |